Form 4: Equillium CFO Jason Keyes Sells 10,000 Shares Under 10b5-1 Trading Plan

Equillium's Chief Financial Officer, Jason Keyes, sold 10,000 shares of common stock at a weighted average price of $0.70, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Jason Keyes, the Chief Financial Officer of Equillium, Inc., sold 10,000 shares of common stock.
• The sale occurred on November 14, 2024, at a weighted average price of $0.70 per share.
• The shares were sold under a pre-arranged 10b5-1 trading plan adopted on March 27, 2024.
• The sale was executed in multiple transactions with prices ranging from $0.67 to $0.76 per share.
• Following the transaction, Mr. Keyes directly owns 73,913 shares and indirectly owns 47,720 shares through The Keyes Trust.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The use of a 10b5-1 trading plan is a common method for executives to sell shares without being accused of insider trading, and many executives at similar companies use these plans.

Stakeholder Impact

• The sale of shares by a company executive may cause some concern among shareholders, but the fact that it was done under a pre-arranged 10b5-1 plan should mitigate those concerns.

Key Dates

Keywords

Equillium, Jason Keyes, SEC Form 4, 10b5-1 trading plan, insider trading, stock sale, CFO